• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Guardant Health, Inc. (GH) Stock Price, News & Analysis

Guardant Health, Inc. (GH) Stock Price, News & Analysis

Currency in USD Disclaimer

$36.89

-$0.22

(-0.59%)

Day's range
$36.57
Day's range
$37.8
50-day range
$20.14
Day's range
$38.53
  • Country: US
  • ISIN: US40131M1099
52 wk range
$15.81
Day's range
$38.53
  • CEO: Dr. Helmy Eltoukhy Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.36
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (GH)
  • Company Guardant Health, Inc.
  • Price $36.89
  • Changes Percentage (-0.59%)
  • Change -$0.22
  • Day Low $36.57
  • Day High $37.80
  • Year High $38.53

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $40.00
  • High Stock Price Target $50.00
  • Low Stock Price Target $36.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.92
  • Trailing P/E Ratio -7.31
  • Forward P/E Ratio -7.31
  • P/E Growth -7.31
  • Net Income $-479,449,000

Income Statement

Quarterly

Annual

Latest News of GH

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Guardant Health, Inc. Frequently Asked Questions

  • What were the earnings of GH in the last quarter?

    In the last quarter Guardant Health, Inc. earnings were on Wednesday, November, 6th. The Guardant Health, Inc. maker reported -$0.45 EPS for the quarter, beating analysts' consensus estimates of -$0.55 by $0.10.

  • What is the Guardant Health, Inc. stock price today?

    Today's price of Guardant Health, Inc. is $36.89 — it has decreased by -0.59% in the past 24 hours. Watch Guardant Health, Inc. stock price performance more closely on the chart.

  • Does Guardant Health, Inc. release reports?

    Yes, you can track Guardant Health, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Guardant Health, Inc. stock forecast?

    Watch the Guardant Health, Inc. chart and read a more detailed Guardant Health, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Guardant Health, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Guardant Health, Inc. stock ticker.

  • How to buy Guardant Health, Inc. stocks?

    Like other stocks, GH shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Guardant Health, Inc.'s EBITDA?

    Guardant Health, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Guardant Health, Inc.’s financial statements.

  • What is the Guardant Health, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.8501652635, which equates to approximately -85.02%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Guardant Health, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Guardant Health, Inc.'s financials relevant news, and technical analysis. Guardant Health, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Guardant Health, Inc. stock currently indicates a “sell” signal. For more insights, review Guardant Health, Inc.’s technical analysis.

  • A revenue figure for Guardant Health, Inc. for its last quarter?

    Guardant Health, Inc. published it's last quarterly revenues at $191.48 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.